The pre-clinical and clinical data derived to date is always of some value. Besides, continuing PTX-200 in the clinic for AML was seen as a less than prudent use of funds given the crowded AML space. Funds are best directed towards PTX-100, giving PTX a foot in the door towards commercialisation.
The other thing to remember is that CellPryme is being kept going. It is a reiteration of PTX-200 for the enhancement of cell therapies, such as CAR-T. The evidence for our patent application just seems to grow: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022241515
When we hear anything about third-party evaluations (by way of a licensing deal) is anyone's guess. Last we heard, CellPryme-A was on its way into the clinic (or so I thought).
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)